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E-mail address: gbpniesj@lg.ehu.es (J.L. Nieva).The broadly neutralizing anti-HIV-1 2F5 monoclonal antibody recognizes a gp41 epitope proximal to
the viral membrane. Potential phospholipid autoreactivity at cell surfaces has raised concerns about
the use of this antibody for development of vaccines or immunotherapy. In this study, confocal
microscopy of giant unilamellar vesicles (GUVs) was used to assess 2F5 reactivity with phospholipids
assembled into bilayers with surface charge and curvature stress approximating those of the
eukaryotic plasma membranes. Antibody partitioning into lipid bilayers required the speciﬁc recog-
nition of membrane-inserted epitope, indicating that 2F5 was unable to directly react with GUV
phospholipids, even under ﬂuid phase segregation conditions. Our results thus support the feasibil-
ity of raising 2F5-like neutralizing responses through vaccination, and the medical safety of mAb
infusions.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recognition in a membrane environment implies the establish-The HIV-1 broadly neutralizing 2F5 monoclonal antibody
(mAb2F5) recognizes the gp41 ELDKWA epitope within the ‘‘mem-
brane-proximal external region” (MPER) domain of Env gp41 sub-
unit (reviewed in [1–3]). This highly conserved gp41 domain is to
date a major focus for HIV-1 vaccine development [1,2]. In addi-
tion, the mAb2F5 antibody is currently under clinical evaluation
in passive immunization studies (reviewed in [4]). The fact that
MPER may favorably insert into membrane interfaces, together
with the presence of a long-hydrophobic CDR H3 loop, suggest that
mAb2F5 might be adapted for recognition of its membrane-associ-
ated epitope [5–9].chemical Societies. Published by E
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ís Vasco, Aptdo. 644, 48080ment of intimate contacts between the antibody and the phospho-
lipid bilayer. Accordingly, 2F5 was early described to bind directly,
albeit with moderate afﬁnity, to (mainly anionic) phospholipids,
including the autoantigen cardiolipin, deposited on ELISA plates
[6,10]. This phenomenon was interpreted as an evidence for auto-
reactivity mechanisms that would hamper anti-MPER neutralizing
responses in vivo, and limit the potential use of anti-MPER mAb-s
for passive immunotherapy [10,11]. Contrasting these observa-
tions, subsequent reassessments based on clinical ELISA failed to
detect signiﬁcant 2F5 reactivity with phospholipids [12,13]. It
was further argued that anti-phospholipid reactivity was unlikely
to evolve at the surface of the plasma membrane in healthy cells
(see reference [14] for a discussion on this issue).
In this work, confocal microscopy of intact giant unilamellar
vesicles (GUVs) was used for the ﬁrst time to directly visualize
mAb2F5 interactions with lipid bilayers bearing a curvature stress
and surface charge comparable to those of the plasma membrane
surrounding eukaryotic cells [15,16]. The plasma membrane bears
an additional level of physicochemical complexity that was also ta-
ken into consideration in our study: the existence of laterally seg-
regated lipid platforms or ‘‘rafts” [17,18]. Consistent with an
antibody-membrane association process strictly dependent onlsevier B.V. All rights reserved.
1592 B. Apellaniz et al. / FEBS Letters 584 (2010) 1591–1596the speciﬁc binding to the membrane-inserted epitope, mAb2F5
partitioning into GUVs was only observed in the presence of epi-
tope-peptide pre-bound to membrane. Quantitative ﬂow-cytome-
try measurements further conﬁrmed that mAb2F5 binding to
vesicles was mediated by speciﬁc recognition of the membrane-in-
serted MPER epitope. Thus, our data support that mAb2F5 is not
able to directly react with phospholipids accessible to the external
leaﬂet of the plasma membrane, not even under ﬂuid phase co-
existence conditions.
2. Materials and methods
The NEQELLELDKWASLWNWFNITNWLWYIK (MPER-2F5) and
NEQELLELAAWASLWNWFNITNWLWYIK (2F5-MPER(9,10)A) pep-
tides were produced by solid-phase synthesis using Fmoc chemis-
try as C-terminal carboxamides and puriﬁed by HPLC at the
Proteomics Unit of the University Pompeu-Fabra (Barcelona,
Spain). Peptide stock solutions were prepared in dimethylsulfoxide
(DMSO, spectroscopy grade) and the concentrations were deter-
mined using a Bicinchoninic Acid microassay (Pierce, Rockford,
IL, USA). Neutralizing antibody expressing hybridomas were origi-
nally generated by combined PEG-electrofusion of peripheral blood
mononuclear cells of HIV infected non-symptomatic patients [19].
The 2F5 mAb used in this study was subsequently produced in re-Fig. 1. Imaging of mAb2F5 binding to GUVs. (A) Confocal microscopy of GUVs (equator
containing 1% (mol:mol) 2F5-MPER or 2F5-MPER(9,10)A (top and bottom panels, respect
detected by incubating the mixture with Alexa Fluor 488 goat anti-human IgG (0.1 lM) f
and center columns, respectively. The right column displays merging of both detection c
relation to the membrane. (B) 3-D reconstruction of 2F5-MPER containing GUVs incubacombinant CHO cells after the subclass switch to IgG1 [20].
1-Palmitoyl-2-oleoylphosphatidylcholine (POPC), dioleoyl-phos-
phatidylcholine (DOPC), sphingomyelin (SPM) and cholesterol
(Chol) were purchased from Avanti Polar Lipids (Alabaster, AL,
USA). 5-Cholesten-3-one (cholestenone) was from Sigma–Aldrich
(St. Louis, MO, USA). The N-(ﬂuorescein-5-thiocarbamoyl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (f-DHPE),
1,19-dioctadecyl-3,3,39,39-tetramethylindodicarbocyanine per-
chlorate (DiD), 1,10-dioctadecyl-3,30-oxacarbocyanine perchlorate
(DiO), and Alexa Fluor 488 ﬂuorescent probes and the Alexa Fluor
488 goat anti-human IgG were fromMolecular Probes (Eugene, OR,
USA). The PE-Cy5 mouse anti-human IgG was purchased from BD
Biosciences.
GUVs of the desired lipid composition were prepared according
to the electroformation method as described in [21]. Planar Sup-
ported-lipid Bilayers (SLBs) were prepared as described in [22].
Confocal ﬂuorescence microscopy of GUVs and SLBs was
performed on a commercial LSM510 system from Zeiss (Jena,
Germany) with a laser scanning module and using multi-track
mode [23]. Image processing and analyses were carried out with
ImageJ (rsb.info.nih.gov/ij/).
Permeabilization measurements were done by adding the GUVs
to a previously stirred PBS solution containing free Alexa Fluor 488
(molecular mass 720 Da) as a marker and the lytic 2F5-MPER pep-ial sections) electroformed from a mixture of POPC:Chol:DiD (4:1:0.01, mole ratio)
ively), and subsequently incubated with mAb2F5 (0.1 lM) for 1 h. 2F5 antibody was
or an additional hour. Lipid (red) and mAb2F5 (green) staining are shown in the left
hannels. The schematic diagram on top of the panels shows 2F5-MPER topology in
ted with mAb2F5. Conditions otherwise as in the previous panel.
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achieve a largely homogeneous distribution of vesicles, marker,
and peptide. After 60 min the number of GUVs into which the mar-
ker had penetrated was counted versus the total number of vesi-
cles in several regions of the sample.
Antibody-vesicle association was determined quantitatively
using a BD FACScalibur Flow Cytometer (Becton Dickinson Immun-
ocytometry Systems, Mountain View, CA) essentially as described
in [7]. Measuring conditions were set for multilamellar vesicles
(MLVs), a lipid concentration of 0.25 mM, and 0.01% ﬂuorescent
phospholipid probe (mole percent). In a typical experiment, ﬂuo-
rescently labeled MLVs doped with peptide epitopes (1:100 pep-
tide:lipid molar ratio) were incubated for 10 minutes with
increasing concentrations of the 2F5 mAb and subsequently, for
5 min with twice the concentration of anti-human immunoglobu-
lin coupled to cyanine (IgG-PE-Cy5).
3. Results and discussion
3.1. Epitope binding-mediated mAb2F5 partitioning into GUV
membranes
Most available data on mAb2F5-phospholipid reactivity have
been obtained in ELISAs under conditions of uncontrolled
phospholipid hydration, and/or using small vesicles composed of
negatively charged lipids [6,10,24–26]. However, electrically neu-
tral phospholipids are generally assumed to be the major compo-
nents of the external leaﬂet of the plasma membrane [15].
Moreover, in the size scale of the phospholipid bilayer width
(4–6 nm), the plasmamembrane can be considered as a ﬂat plane
devoid of curvature stress. The absence of curvature stress, in com-
bination with the molecular cohesion induced by the high levels of
Chol [16], pose an effective restriction to the insertion of externalFig. 2. Effect of mAb2F5 on 2F5-MPER permeabilizing activity measured in GUVs. (A
incubation in a solution colored with soluble Alexa-488 (green) at 300 nM. CTL: untre
incubated with 0.5 lM peptide that were permeabilized to Alexa-488. +2F5-MPER/+mAb
with 0.5 lM mAb2F5. The number of permeabilized vesicles was signiﬁcantly reduced i
previous samples. The +mAb2F5/+2F5-MPER column corresponds to a sample that conta
values of 2–4 ﬁelds counted ± S.D. are shown. All values were signiﬁcantly lower (0.001 <
column).agents into the lipid bilayer surrounding cells. Thus, giant vesicles
with sizes comparable to those of cells and composed of POPC and
Chol provide bona ﬁde starting models to analyze mAb2F5 associ-
ation with membranes emulating the external leaﬂet of the plasma
membrane.
The confocal micrographs displayed in Fig. 1A correspond to
equatorial sections of GUVs electroformed from a mixture of lipids
and 2F5-MPER peptides and labeled with the lipophilic probe DiD
(depicted in red). Control experiments using a ﬂuorescently labeled
peptide indicated that 2F5-MPER could be efﬁciently incorporated
into GUV bilayers following this procedure (see Supplementary
Fig. 1). GUVs containing peptide epitope were incubated with
mAb2F5, which was subsequently imaged with a secondary anti-
body labeled with Alexa Fluor 488 (depicted in green). mAb2F5
could be detected in association with 2F5-MPER containing mem-
branes following this procedure (Fig. 1A, top panels). The speciﬁcity
of this binding process was tested using the 2F5-MPER(9,10)Ala
peptide, in which Ala substituted for Asp9 and Lys10, two residues
that are crucial for the neutralizing activity and binding of the 2F5
mAb [27]. In the 2F5-MPER(9,10)Ala-containing samples Alexa-
stain appeared as a uniform bright background, against which the
vesicles were seen as dark objects. This ﬂuorescence pattern de-
noted that neither the labeled antibody, nor mAb2F5 associated
with GUVs under these conditions (Fig. 1A, bottom panels).
The previous data clearly indicate that MAb2F5 partitioning
into the POPC:Chol GUVs was not spontaneous, but mediated by
the speciﬁc recognition of the 2F5 epitope sequence anchored to
the membrane (see also Fig. 4 below). The 3-D reconstruction of
the MAb2F5-labeled GUV-s showed a homogeneous distribution
of the Alexa Fluor 488 label on the surface of the vesicle
(Fig. 1B). Thus, in addition to the speciﬁcity of the process, epitope
recognition in the lipid bilayer surface of GUVs did not result in the
formation of discernable antibody aggregates.) Confocal microscopy pictures of DiD-labeled POPC:Chol (4:1) GUVs after 2 h of
ated control vesicles showing unaltered permeability barrier. +2F5-MPER: vesicles
2F5: vesicles were incubated with 0.5 lM peptide and, after 10 min, supplemented
n these samples. (B) Quantiﬁcation of the number of vesicles permeabilized in the
ined 0.5 lM mAb2F5 in solution prior to the addition of GUVs and peptide. Average
P < 0.01) than the percentage of vesicles permeabilized by the peptide (+2F5-MPER
Fig. 3. Effect of ﬂuid phase co-existence on mAb2F5 binding and peptide epitope recognition. (A) Top panels: confocal microscopy images of DiO-labeled DOPC:SPM:Chol
(2:2:1) GUVs electroformed with 1% of rhodamine-labeled 2F5-MPER peptide. Lipophilic dye DiO (left) and rhodamine-labeled peptide (center) are depicted in green and red,
respectively. DiO speciﬁcally partitions into Ld phase. Therefore, Lo domains are seen as dark areas in DOPC:SPM:Chol (2:2:1) samples. Peptide and lipid signals superimposed
in both samples indicated that 2F5-MPER was excluded from the Lo domains (right). Middle panels: pictures of DiD-labeled DOPC:SPM:Chol (2:2:1) GUVs incubated with
mAb2F5 (0.1 lM) for 1 h. DiD dye (red) speciﬁcally labels the Ld phase (left). The 2F5 antibody was detected with Alexa Fluor 488 goat anti-human IgG, but this dye remained
soluble in solution (green background, center and right). Bottom panels: Images of DOPC:SPM:Chol (2:2:1) GUVs electroformed with 1% of rhodamine-labeled 2F5-MPER
peptide and incubated with mAb2F5 (0.1 lM) for 1 h. The rhodamine label is depicted in red (left) and the 2F5 antibody was imaged with green Alexa Fluor 488 goat anti-
human IgG (center). Both labels co-localize within the same domains (right). (B) 2F5 epitope recognition in supported-lipid bilayers. Confocal images of DiD-labeled
DOPC:SPM:Chol (2:2:1) lipid bilayers deposited on mica supports. The untreated CTL samples (top panels) display the speciﬁc DiD labeling of Ld domains (depicted in red, left
column). The green signal arising from Alexa Fluor 488 goat anti-human IgG is background noise and indicates no antibody binding (center column). Incubation with 2F5-
MPER (0.1 lM) and mAb2F5 (0.1 lM) at intervals of 1 h (middle panels), gave rise to co-localization of DiD and Alexa Fluor 488 into Ld domains (right column). In these
samples, brighter green spots could be observed against a more homogeneously labeled green background (center), which appeared as yellow spots in the merged image
(right).
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was additionally obtained from the inhibitory effect exerted by
mAb2F5 on MPER lytic activity (Fig. 2). The MPER domain has been
proposed to be functional in HIV-1 fusion by perturbing the mem-
brane following an activity pattern similar to that displayed by cer-
tain Trp-rich antimicrobial peptides [28]. 2F5-MPER added
externally to the GUV suspension also incorporated efﬁciently into
bilayers (Supplementary Fig. 1), and permeabilized these vesicles
to a soluble dye (Supplementary Fig. 2). As shown in Fig. 2, this
membrane permeabilization phenomenon could be signiﬁcantly
inhibited in GUVs by the addition of mAb2F5.3.2. Fluid phase co-existence effect on mAb2F5 association with GUVs
Overall, the results displayed in Figs. 1 and 2 support the speciﬁc
recognition and blocking of the membrane-buried 2F5 epitope un-
der conditions that emulate the curvature stress and surface charge
of the plasma membrane. They also rule out the existence of direct
mAb association with the bare lipid bilayer under those conditions.
However, in terms of modeling interactive properties of cell plasma
membranes it is also necessary to account for ﬂuid phase immisci-
bility [17,18]. It is generally assumed that certain proteins can
selectively partition into lipid rafts [17], while insertion of others
Fig. 4. 2F5 mAb association with 2F5-MPER-containing vesicles as determined by
ﬂow-cytometry. POPC:Chol (4:1) and DOPC:SPM:Chol (2:2:1) MLVs (panels A and B,
respectively) were prepared by co-dispersing 2F5-MPER (left panels) or 2F5-
MPER(9, 10)A (right panels) with lipids (1:100 peptide-to-lipid molar ratio).
Vesicles (0.25 mM lipid) were incubated with 0 (black), 5 (blue), 10 (red) or 20
(green) lg/ml of mAb2F5.
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that may exist within raft-domain boundaries [29]. The possibility
existed that the mAb2F5 long-hydrophobic CDR H3 loop might
intersperse between lipids at these membrane sites, thereby pro-
moting antibody partitioning into bilayers under conditions of ﬂuid
phase co-existence. Therefore, in the next set of experiments we
sought to analyze the effect of Lo (liquid-ordered) + Ld (liquid-dis-
ordered) lipid phase co-existence on antibody partitioning and rec-
ognition of the membrane-inserted epitope (Fig. 3).
GUVs composed of ternary mixtures of unsaturated PC, SPM and
Chol mimic the chemical composition and the properties of the li-
pid rafts found in the plasma membrane [23,30]. Accordingly,
GUVs composed of DOPC:SPM:Chol (2:2:1, mole ratio) show lipid
phase separation (Fig. 3A). Vesicles in the top panels of Fig. 3A dis-
play Ld phase labeled with DiO (green), and mostly unlabeled Lo
domains. Rhodamine-labeled 2F5-MPER peptide was found to co-
localize with DiO, indicating that the peptide was segregated into
the disordered Ld domains. Confocal images displayed in the mid-
dle panels rule out the possibility that the mAb2F5 molecule might
speciﬁcally associate with rafts and/or directly insert into domain
boundaries. In these samples DiD dye was used to label Ld phase
(depicted in red). The Alexa-488-labeled secondary antibody
(green) remained in solution, and could not be observed in contact
with the vesicles upon incubation with mAb2F5. In sharp contrast,
mAb2F5 associated with vesicles containing the 2F5-MPER peptide
(bottom panels). The use of rhodamine-labeled peptide allowed
the co-localization of 2F5-MPER and mAb2F5 within the ﬂuid dis-
ordered Lo domains. The 3-D projections of representative GUVs
displayed in the Supplementary Fig. 3 provide further evidence
for the absence of 2F5-MPER or mAb2F5 aggregation at the surface
of GUVs. They also rule out preferential peptide and/or antibody
localization at the boundaries between domains.
In conjunction, the data presented in Fig. 3A demonstrate that
under conditions allowing ﬂuid phase co-existence, 2F5 epitope
recognition also mediates the recruitment of mAb2F5 molecules
into the surface of GUVs. Liquid domain co-existence and interact-
ing proteins can be also directly visualized by confocal microscopy
of supported-lipid bilayers (SLBs) [31]. In supported DOPC:SPM:-
Chol (2:2:1) bilayers, DiD was also excluded from the ordered do-
mains, which were observed as dark areas (Fig. 3B, left-hand
panels). Similarly to what it was observed in the GUV system,
mAb2F5 associated with the disordered domains in the presence
of 2F5-MPER peptide. However, in comparison to the vesicular sus-
pensions, in this system certain degree of mAb2F5 aggregation
could be evidenced from the existence of spots with more intense
green ﬂuorescence. Given the fact that similar aggregates were not
observed in association with GUVs, we infer that the formation of
these aggregates is inherent to the SLB experimental conditions or
sample preparation.
3.3. mAb2F5 association with lipid bilayers determined by ﬂow-
cytometry
Association of mAb2F5 with unstressed lipid bilayers was quan-
titatively assessed by ﬂow-cytometry of MLVs (Fig. 4). For the case
of 2F5-MPER-containing POPC:Chol vesicles, an increase in anti-
body ﬂuorescence was apparent after incubation with a mAb2F5
dose of 20 lg/ml (green line in panel A, left). By comparison, for
DOPC:SPM:Chol (2:2:1) vesicles containing 2F5-MPER peptide (B,
left-panel), a distinct population of labeled vesicles was clearly dis-
cernible at a lower antibody concentration of 5 lg/ml (blue line),
which increased in ﬂuorescence intensity at 10 lg/ml antibody
(red line). The negative control samples of vesicles containing
2F5-MPER(9, 10)A peptide (A, B, right panels) did not show a sig-
niﬁcant ﬂuorescence increase even upon incubation with 20 lg/
ml antibody.Thus, the ﬂow-cytometry results conﬁrmed that antibody parti-
tioning into both types of membranes was dependent on the spe-
ciﬁc recognition of the epitope sequence. Interestingly, they also
revealed that the amount of mAb2F5 speciﬁcally bound to mem-
brane-inserted epitope increased in the vesicles displaying ﬂuid
phase co-existence. The preceding confocal microscopy analysis
was consistent with 2F5 epitope recognition occurring within Ld
domains under phase co-existence. The conﬁnement of 2F5-MPER
into Ld domains results in the local increase of the peptide epitope
surface concentration. Consequently, we infer that the more efﬁ-
cient mAb binding observed in Lo phase-containing vesicles can
be attributed not to speciﬁc interactions with Chol or sphingomy-
elin but, rather, to an increase in the mAb binding avidity.
Finally, we note that our data do not rule out unambiguously
the existence of mAb2F5 polyreactivity towards individual lipid
species not taken into consideration in our study. In particular,
Matyas et al. [26] reported certain degree of mAb2F5 binding to
pure monohexosylceramides deposited on ELISA plates. While
the ELISA may not be the method of choice to determine the bind-
ing speciﬁcity of the mAb2F5, the absence of binding to these lipids
in the same ELISA assay of 2G12, an antibody binding to a gp120
epitope, implies a grade of speciﬁc recognition. Brügger et al.
[32] determined that approximately 600 monohexosylceramide
molecules are indeed incorporated into the raft virion membrane
(i.e. 0.004 mol%). Thus, we decided to assay direct recognition
of these molecules in the context of the unstressed membranes
used in our study. The ﬂow-cytometry results displayed in the Sup-
plementary Fig. 4 indicate that inclusion of galactosyl ceramide
(Gal-CER) at the membrane load used to test 2F5-MPER recognition
(i.e., 1 mol%, Fig. 4, left panels) did not promote mAb2F5 associa-
tion with vesicles. We conclude that this molecule was not directly
bound by mAb2F5 under those conditions.
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mAb2F5 polyreactivity with phospholipids has been claimed to
limit its use in vaccine development and immunotherapy (see ref-
erence [14] for a comprehensive discussion on this issue). How-
ever, the capacity of 2F5 for binding phospholipids and the
functional relevance of that phenomenon is presently a matter of
debate. From a structural point of view, the presence of the hydro-
phobic CDR H3 loop, in combination with positively charged para-
tope surfaces, are likely to promote mAb2F5 adsorption to
phospholipids immobilized onto solid supports [6,10,26]. This
non-speciﬁc mechanism would also operate at the surface of small
vesicles that are subject to lateral pressure allowing easier access
to the hydrocarbon core [24].
In contrast, our GUV confocal microscopy study demonstrates
that direct association of mAb2F5 with membranes does not occur
in the context of unstressed bilayers mimicking the conditions
existing at the plasma membrane. The undetectable water-mem-
brane partitioning observed in the GUV system therefore supports
the absence of mAb2F5 reactivity to phospholipids at the cell sur-
face. The antibody was only found in contact with GUVs bearing
surface-bound 2F5-MPER peptide. This ﬁnding reinforces the no-
tion that stable antibody insertion into lipid bilayers may take
place after speciﬁc recognition of membrane embedded epitope se-
quence, but not before.
Also in line with that idea, ﬂow-cytometry measurements re-
vealed an enhancement of mAb2F5 binding to membrane-inserted
epitope in vesicles displaying ﬂuid phase co-existence, consistent
with the increase in surface concentration of MPER peptide segre-
gated into Ld domains. We speculate here that this topological
restriction might favorably affect the efﬁciency as multivalent
immunogens of liposomal formulations destined for vaccination.
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